DOCK1 insufficiency disrupts trophoblast function and pregnancy outcomes via DUSP4-ERK pathway
Life Science Alliance · 2024
DOI: 10.26508/lsa.202302247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Yichi Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Abortion, Spontaneous, Premature Birth. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Funds for Outstanding Newcomers, Shanghai Sixth People’s Hospital.
Abstract (Originalsprache)
Abnormal trophoblast function is associated with diseases such as recurrent spontaneous abortion, pre-eclampsia, and preterm birth, and endangers maternal and fetal health. However, the underlying regulatory mechanisms remain unclear. In this study, we found DOCK1 expression is decreased in the placental villi of patients with recurrent spontaneous abortion, and that its expression determined the invasive properties of extravillous trophoblasts (EVTs), highlighting a previously unknown role of DOCK1 in regulating EVT function. Furthermore, DOCK1 deficiency disturbed the ubiquitinated degradation of DUSP4, leading to its accumulation. This caused inactivation of the ERK signaling pathway, resulting in inadequate EVT migration and invasion. DOCK1 was implicated in regulating the ubiquitin levels of DUSP4, possibly by modulating the E3 ligase enzyme HUWE1. The results of our in vivo experiments confirmed that the DOCK1 inhibitor TBOPP caused miscarriage in mice by inactivating the DUSP4/ERK pathway. Collectively, our results revealed the crucial role of DOCK1 in the regulation of EVT function via the DUSP4-ERK pathway and a basis for the development of novel treatments for adverse pregnancy outcomes caused by trophoblast dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
- Institute of Birth Defects and Rare Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Automation, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
- Key Laboratory of System Control and Information Processing, Ministry of Education of China, Shanghai, China.
- Department of Pediatrics, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Funds for Outstanding Newcomers, Shanghai Sixth People’s Hospital
- Innovative Research Team of High-Level Local Universities in Shanghai
- Shanghai Jiao Tong University Trans-Med Awards Research (STAR)
- Natural Science Foundation of Shanghai
- Shanghai Pujiang Program
Zitieren
APA
Xu, Y., Liu, X., Zeng, W., Zhu, Y., Dong, J., Wu, F., Chen, C., Sharma, S., & Lin, Y. (2024). DOCK1 insufficiency disrupts trophoblast function and pregnancy outcomes via DUSP4-ERK pathway. Life Science Alliance. https://doi.org/10.26508/lsa.202302247
Vancouver
Xu Y, Liu X, Zeng W, Zhu Y, Dong J, Wu F, et al. DOCK1 insufficiency disrupts trophoblast function and pregnancy outcomes via DUSP4-ERK pathway. Life Science Alliance. 2024. doi:10.26508/lsa.202302247
BibTeX
@article{Xu2024,
author = {Xu, Yichi and Liu, Xiaorui and Zeng, Weihong and Zhu, Yueyue and Dong, Junpeng and Wu, Fan and Chen, Cailian and Sharma, Surendra and Lin, Yi},
title = {DOCK1 insufficiency disrupts trophoblast function and pregnancy outcomes via DUSP4-ERK pathway},
journal = {Life Science Alliance},
year = {2024},
doi = {10.26508/lsa.202302247}
}
EUVIMED